Life Sciences

Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
December 31, 2018
Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.
December 20, 2018
While many medical interventions—from vaccines, anesthesia, antibiotics, and even eyeglasses—have initially seemed like playing god, interventions to manipulate directly the heritable genetic endowment fundamental not only to what makes us human, but to what makes each of us unique, had never been seen before.
November 15, 2018
Stephen Ezell gave the keynote presentation at the Life Sciences Tennessee Annual Conference on innovation economics and how smart public policies can stimulate Tennessee’s growing life-sciences innovation sector.
November 10, 2018
As Rob Atkinson writes for The Hill, price controls and other steps to reduce drug company revenues would stifle knowledge generation and sharing, leaving future generations less access to effective new drugs than would otherwise be the case.
November 5, 2018
A considerable share of biopharma research “spills over” and contributes to knowledge discovery and drug development overall, not just in individual firms’ labs.
September 24, 2018
The Non-GMO Project food label deliberately deceives and misleads consumers in violation of the Federal Food, Drug and Cosmetic Act. ITIF petitions FDA to prohibit such labels.
September 13, 2018
ITIF's Center for Data Innovation will host a public forum with key stakeholders from government, the private sector, and academia to discuss the latest developments in using data to improve health care outcomes, reduce health care costs, and empower patients.
August 24, 2018
A contagion of poor public policy is sweeping across Latin America in the form of the spreading use of compulsory licenses on novel pharmaceutical drugs, and it threatens to undermine the very ecosystem supporting the development of medicines designed to treat deadly diseases in the first place.
June 28, 2018
As ITIF’s Stephen Ezell and Richard Owens of the Macdonald Laurier Institute write for the Financial Post, free-riding on drug prices is an example of how Canada refuses to step up to what is required for a globally leading innovation culture.
June 18, 2018
If drug price controls were lifted throughout the OECD, the number of new treatments available would increase 8 to 13 new drug compounds by 2030, writes John Wu in Innovation Files.

Pages